Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness
Triple Therapy With Boceprevir Versus Dual Therapy in Patients With HCV Genotype 1 Infection: Adverse Effects
Triple therapy with boceprevir for 48 weeks (pegylated interferon alfa-2b plus ribavirin for 4 weeks plus boceprevir for another 44 weeks) was associated with increased risk of neutropenia (2 trials; pooled relative risk [RR], 1.8; 95-percent confidence interval [95% CI], 1.5 to 2.3), dysgeusia (2 trials; pooled RR, 2.5; 95% CI, 2.0 to 3.2), anemia (2 trials; pooled RR, 2.0; 95% CI, 1.4 to 2.8), and thrombocytopenia (2 trials; pooled RR, 3.3; 95% CI, 1.3 to 8.6) than with dual therapy (pegylated interferon alfa-2b plus ribavirin). With triple therapy, the incidence of anemia was about 50 percent, the incidence of neutropenia was about 25 percent, the incidence of severe anemia was 4–5 percent, and the incidence of severe neutropenia was 8–15 percent. There was no difference in the overall risk of withdrawal due to adverse events between the two treatment groups. The strength of evidence for this finding was rated moderate.
Keywords: finding | outcome | hepatitis C | HCV | treatment | triple therapy | adverse effects | strength of evidence
- Chou R, Hartung D, Rahman B, et al. Treatment for Hepatitis C Virus Infection in Adults: A Comparative Effectiveness Review. Evidence Report No. 76 (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC113-EF. Available at www.effectivehealthcare.ahrq.gov/hepctreatment.cfm.
Your slide tray is being processed.